Odyssean LLC Increases Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

Odyssean LLC increased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 149.9% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 29,924 shares of the company’s stock after purchasing an additional 17,952 shares during the quarter. Mirum Pharmaceuticals comprises approximately 0.6% of Odyssean LLC’s portfolio, making the stock its 8th biggest holding. Odyssean LLC’s holdings in Mirum Pharmaceuticals were worth $3,503,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Contravisory Investment Management Inc. increased its position in Mirum Pharmaceuticals by 2.3% during the 2nd quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock worth $539,000 after buying an additional 103 shares during the period. ABS Investment Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $245,847,000. Faithward Advisors LLC boosted its position in shares of Mirum Pharmaceuticals by 0.5% in the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock valued at $2,537,000 after acquiring an additional 126 shares during the period. Janney Montgomery Scott LLC boosted its position in shares of Mirum Pharmaceuticals by 6.7% in the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock valued at $253,000 after acquiring an additional 200 shares during the period. Finally, Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period.

Mirum Pharmaceuticals Stock Up 0.3%

MIRM stock opened at $100.90 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $63.23 and a 52 week high of $130.00. The business has a 50-day simple moving average of $109.09 and a 200 day simple moving average of $101.73. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The company has a market cap of $6.55 billion, a PE ratio of -6.93 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. During the same quarter in the previous year, the company earned ($0.12) earnings per share. The company’s quarterly revenue was up 37.9% on a year-over-year basis. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 658 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the transaction, the senior vice president directly owned 616 shares of the company’s stock, valued at $61,600. This trade represents a 51.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the transaction, the chief financial officer owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. This represents a 14.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 133,814 shares of company stock valued at $13,914,562. Company insiders own 8.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on MIRM shares. HC Wainwright lowered their price target on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Wolfe Research began coverage on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 target price on the stock. Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. Morgan Stanley set a $137.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $123.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $137.31.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.